Verastem (VSTM) Total Liabilities (2011 - 2026)
Verastem (VSTM) posted quarterly Total Liabilities of $146.0 million for Q1 2026, down 11.03% year-over-year from $164.1 million in Q1 2025, and down 22.83% quarter-over-quarter from $189.2 million in Q4 2025.
Analysis
Verastem (VSTM) Total Liabilities (2011 - 2026) Analysis & Trends
Verastem's Total Liabilities history runs 16 years deep, the most recent figure standing at $146.0 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 11.03% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $146.0 million (down 11.03% YoY), while the FY2025 annual figure was $189.2 million, up 45.09% from the prior year.
- Total Liabilities for Q1 2026 stood at $146.0 million, down from $189.2 million in the prior quarter.
- The five-year high for Total Liabilities was $192.4 million in Q3 2025, with the low at $43.4 million in Q1 2022.
- The 5-year median for Total Liabilities is $71.8 million (2023), against an average of $99.1 million.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities soared 197.26% in 2022, then retreated 11.03% in 2026.
- Verastem's Total Liabilities stood at $47.7 million in 2022, then surged by 49.36% to $71.2 million in 2023, then surged by 83.23% to $130.4 million in 2024, then jumped by 45.09% to $189.2 million in 2025, then dropped by 22.83% to $146.0 million in 2026.
- Business Quant data shows VSTM's Total Liabilities at $146.0 million in Q1 2026, $189.2 million in Q4 2025, and $192.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 156.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 156.53 Mn |
| Mar 31, 2026 | 146.03 Mn |
| Dec 31, 2025 | 189.25 Mn |
| Sep 30, 2025 | 192.38 Mn |
| Jun 30, 2025 | 160.21 Mn |
| Mar 31, 2025 | 164.13 Mn |
| Dec 31, 2024 | 130.43 Mn |
| Sep 30, 2024 | 94.16 Mn |
| Jun 30, 2024 | 65.74 Mn |
| Mar 31, 2024 | 77.32 Mn |
| Dec 31, 2023 | 71.19 Mn |
| Sep 30, 2023 | 71.81 Mn |
| Jun 30, 2023 | 69.01 Mn |
| Mar 31, 2023 | 66.69 Mn |
| Dec 31, 2022 | 47.66 Mn |
| Sep 30, 2022 | 48.22 Mn |
| Jun 30, 2022 | 46.52 Mn |
| Mar 31, 2022 | 43.38 Mn |
| Dec 31, 2021 | 21.10 Mn |
| Sep 30, 2021 | 16.22 Mn |